Home > Formulary : Adult > Recent Decisions > 2022 >
Decisions 14th June 2022
At the meeting on the 14th June, the following decisions were agreed
New Drug Requests
Approved
Dexmedetomidine (TLS Red)
-
For sedation during awake fibre-optic intubation for patients with opioid dependence or who are at higher risk of respiratory depression, hypoxia and over-sedation
Ketamine (TLS Red)
-
For management of behavioural disturbance in the Emergency Department
Dienogest tablets (TLS Amber No Shared Care Protocol)
-
For adult female patients with confirmed or suspected endometriosis
Yes! vaginal moisturiser (TLS Green)
-
For vaginal atrophy in post-menopausal women with oestrogen sensitive conditions for whom topical oestrogens are not suitable.
Shared Care Protocols
Approved
-
New - Budesonide orodispersible tablets (Jorveza) Shared Care Protocol for maintenance treatment of eosinophilic oesophagitis Shared Care Protocol and Pathway.
-
Updated - Colesevelam Shared Care Protocol for treatment of bile acid malabsorption
Other Formulary Decisions:
-
Diabetes Chapter Review - proposed amendments approved. Changes include: addition of links. Tolbutamide and glimepride restricted to existing patients only, nateglinide, test strips for secondary care specifically, urinalysis strips all removed from formulary. Future TLS applications expected for SGLT2i's, DPP-4i's, GLP-1s. Table layout for insulin section will be updated/amended.
-
Dapsone tablets - for treatment of dermatoses and oral ulceration to be included on the BNSSG Adult Joint Formulary as TLS Amber 3 months once a shared care protocol has been developed and approved and there has been clarification of the monitoring requirements..
-
Salbutamol tablets - to be removed from the Joint Formulary
Further work
-
Guanfacine Shared Care Protocol - Further work to review delivery of shared care required for Joint Formulary Group to assess application.